Table 1 Patient characteristics in LD-SCLC according to timepoint of start of irradiation
Limited disease (57) | Early start 24 | Late start 25 | Very late start 8 |
|---|---|---|---|
Sex | |||
Male | 16 (66.67) | 8 (32.00) | 5 (62.50) |
Female | 8 (33.32) | 17 (68.00) | 3 (37.50) |
Age | |||
Average | 65.36 | 64.79 | 67.81 |
Range | 45–78 | 49–70 | 60–84 |
Karnofsky performance status | |||
Median | 80 | 70 | 80 |
50–70 | 11 (45.83) | 14 (56.00) | 2 (25.00) |
80–100 | 13 (54.17) | 11 (44.00) | 6 (75.00) |
Chemotherapy regimens | |||
CE (platinum derivatives/etoposide) | 13 (54.17) | 18 (72.00) | 5 (62.50) |
CEA (platinum derivatives/etoposide/ antibodies) | 3 (12.50) | 4 (16.00) | 0 (0.00) |
Others | 8 (33.33) | 3 (12.00) | 3 (37.5) |
Time to irradiation | |||
Median in days | 43 | 75 | 139.5 |
Range | 21–105 | 45–152 | 83–329 |
Concepts of doses | |||
2Â Gy up to 50Â Gy | 1 (4.17) | 11 (44.00 | 2 (25.00) |
2 Gy up to 50 Gy + 10 Gy Boost | 16 (66.67) | 14 (56.00) | 4 (50.00) |
Others | 7 (29.17) | 0 (0.00) | 2 (25.00) |
Planning Target Volume in cm3 | |||
Median | 684.67 | 614.00 | 670.54 |
Range | 7.78–2239.29 | 245.91–1905.74 | 134.18–1002.61 |
Mean lung dose in Gy | |||
Median | 13.78 | 15.22 | 14.69 |
Range | 1.42–19.49 | 10.25–22.39 | 7.64–18.68 |
Mean lung volume in ccm | |||
Median | 3645.94 | 3625.67 | 3046.75 |
Range | 1960.39–5191.14 | 1856.19–6143.98 | 2354.10–4517.23 |
V5 in ccm | |||
Median | 2170.78 | 2144.41 | 1729.40 |
Range | 981.7–3779.65 | 1093.65–4235.21 | 1453.84–2519.97 |
V20 in ccm | |||
Median | 925.15 | 1029.65 | 934.38 |
Range | 634.48–1695.67 | 437.77–1625.65 | 653.2–1162.65 |
Mean heart dose in Gy | |||
Median | 19.81 | 20.00 | 13.24 |
Range | 6.91–29.99 | 3.49–28.58 | 4.12–34.52 |
Maximum dose esophagus in Gy | |||
Median | 50.9 | 51.1 | 50.6 |
Range | 20.4–52.6 | 42.00–55.00 | 26.9–52.6 |
Prophylactic cranical irradiation | 5 (20.83) | 3 (12.00) | 3 (37.50) |
2Â Gy up to 30Â Gy | 5 (20.83) | 2 (8.00) | 3 (37.50) |
others | 0 (0.00) | 1 (4.00) | 0 (0.00) |
Toxicity at least 1 | 16 (66.67) | 17 (68.00) | 6 (75.00) |
Pneumonitis | 3 (12.50) | 7 (28.00) | 3 (37.50) |
Remission status after thoracic radiation | |||
Not stated | 1 (4.17) | 1 (4.00) | 0 (0.00) |
Stable | 2 (8.34) | 2 (8.00) | 2 (25.00) |
Partial remission | 12 (50.00) | 12 (48.00) | 3 (37.50) |
Complete remission | 4 (16.67) | 7 (28.00) | 2 (25.00) |
Progressive disease | 5 (20.83) | 3 (12.00) | 1 (12.50) |
Progression-free survival (PFS) in months | |||
Median after date of diagnosis | 11.8 (4.7–18.8) | 15.2 (7.3–23.2) | 47.9 (0.0–97.2) |
Median after thoracic radiation | 7.5 (1.6–13.4) | 11.9 (3.1–20.6) | 9.4 |
Overall survival (OAS) in months | |||
Median after date of diagnosis | 23.7 (16.6–30.8) | 22.0 (15.8–28.2) | – |
Median after thoracic radiation | 22.3 (13.5–31.1) | 18.5 (11.5–25.6) | – |
2-year overall survival rate after date of diagnosis | 10 (41.67) | 13 (52.00) | 4 (50.00) |